Welcome to our dedicated page for Scorpius Holdings news (Ticker: SCPX), a resource for investors and traders seeking the latest updates and insights on Scorpius Holdings stock.
Scorpius Holdings Inc (SCPX) is a leading contract development and manufacturing organization (CDMO) accelerating biologic and cell therapy programs through integrated analytical testing, process development, and advanced manufacturing services. This news hub provides investors and industry professionals with essential updates on the company's operational milestones, regulatory developments, and strategic partnerships.
Access real-time updates on Scorpius Holdings' progress in biomanufacturing innovation, including earnings announcements, facility expansions, and collaborations supporting pandemic preparedness initiatives. Our curated news collection enables efficient tracking of critical developments impacting the company's position in the biologics CDMO sector.
Key content categories include clinical manufacturing achievements, quality system enhancements, analytical method validations, and strategic alliances with biotech innovators. All updates are sourced directly from official company communications and verified industry reports.
Bookmark this page for streamlined access to Scorpius Holdings' latest advancements in cell therapy manufacturing and bioprocess optimization. Check regularly for updates on technology platform deployments and regulatory submissions that demonstrate the company's growing capabilities in complex therapeutic development.
Scorpius Holdings (NYSE American: SCPX), an integrated contract development and manufacturing organization (CDMO), has been selected to join the Medical CBRN Defense Consortium (MCDC). The MCDC, established in 2015 under the U.S. Department of Defense, focuses on advancing medical countermeasures against chemical, biological, radiological, and nuclear (CBRN) threats.
As a member, Scorpius will contribute its proprietary expertise to accelerate innovations addressing CBRN threats. This membership allows Scorpius to engage with government stakeholders, collaborate with other companies and academic institutions, and pursue funding opportunities aligned with the DoD's medical CBRN defense priorities.
Jeff Wolf, CEO of Scorpius, stated that this selection reinforces the company's commitment to developing therapies protecting both military personnel and civilians. The membership represents a significant milestone in Scorpius' efforts to contribute to U.S. biosecurity and national defense.
Scorpius Holdings (NYSE American: SCPX) has signed a contract to provide bioanalytical services for a publicly traded clinical-stage immuno-oncology company. This collaboration opens the door for potential expansion into additional analytical work and future GMP manufacturing. The contract validates Scorpius' expertise in delivering critical bioanalytical and process development services, solidifying its position as a trusted partner in the biologics manufacturing space.
CEO Jeff Wolf highlighted the contract as a clear validation of Scorpius' comprehensive capabilities, including advanced bioanalytical services. The company's state-of-the-art facilities enable it to offer an integrated solution meeting the diverse needs of biologics manufacturers. Scorpius is excited about the potential to further develop this partnership and provide ongoing support to advance the client's clinical programs.
Scorpius Holdings (NYSE American: SCPX) commends the U.S. House of Representatives for passing the BIOSECURE Act with strong bipartisan support (306-81 vote). This legislation aims to secure America's pharmaceutical supply chain, strengthen national biosecurity, and improve preparedness for public health emergencies. The Act restricts U.S. Government-funded drug developers from contracting with select China-based biomanufacturing companies, potentially increasing demand for domestic production capabilities.
Scorpius CEO Jeff Wolf anticipates significant opportunities to expand the company's project pipeline as a result of this legislation. As a U.S.-based integrated contract development and manufacturing organization (CDMO), Scorpius is positioned to support biopharmaceutical companies navigating these changes with its cutting-edge expertise and modern facilities.
Scorpius Holdings (NYSE American: SCPX) has been selected for the Biomedical Advanced Research and Development Authority's (BARDA) Rapid Response Partnership Vehicle (RRPV). This collaboration aims to accelerate the development of medical countermeasures for public health threats, including pandemic preparedness and emerging infectious diseases. As an RRPV member, Scorpius will work with BARDA and other federal partners to support product and technology development in critical areas such as vaccines and therapeutics.
Scorpius' biomanufacturing capabilities and state-of-the-art facilities position it to meet the needs of government agencies responding to biological threats. The company's manufacturing platform is designed for flexibility, enabling swift responses to emerging health threats. This selection highlights Scorpius' ability to innovate in the rapidly evolving landscape of biomanufacturing.
Scorpius Holdings (NYSE American: SCPX), a contract development and manufacturing organization (CDMO), has released a corporate update highlighting significant progress. The company has expanded its manufacturing capabilities for biologics and cell therapies, resulting in a threefold increase in revenue for the first half of 2024. Scorpius now boasts a sales pipeline exceeding $100 million in weighted opportunities across biopharmaceutical and government sectors.
The company recently raised $14.4 million in gross proceeds to support growth and attract larger customers. Scorpius is transitioning key clients from process development to full-scale manufacturing, aiming to achieve positive cash flow in the near future. Management compensation is being aligned with growth objectives, contingent on meeting sales targets and booking goals.
Scorpius Holdings (NYSE American: SCPX) reported a 16% year-over-year revenue increase and a 25% reduction in operating expenses for Q2 2024. The company's pipeline now exceeds $100 million in weighted opportunities across government and manufacturing sectors. Q2 2024 financial highlights include:
- Revenue: $0.8 million (up from $0.7 million in Q2 2023)
- Cost of revenues: $0.8 million (up from $0.4 million)
- R&D expenses: $3.6 million (down from $5.2 million)
- SG&A expenses: $5.0 million (down from $7.0 million)
- Net loss: $8.9 million or ($26.98) per share (improved from $13.9 million or ($106.67) per share)
As of August 19, 2024, Scorpius had approximately $13.2 million in cash and short-term investments, strengthening its balance sheet to capitalize on upcoming projects and potentially achieve positive cash flow.
Scorpius Holdings, Inc. (NYSE American: SCPX), a contract development and manufacturing organization (CDMO), has closed its underwritten public offering of 14,375,000 shares of common stock and/or pre-funded warrants. The offering, priced at $1.00 per share, raised gross proceeds of $14,375,000. This includes the full exercise of the underwriter's over-allotment option. ThinkEquity acted as the sole book-running manager for the offering.
The company plans to use the net proceeds for working capital and general corporate purposes. Scorpius Holdings specializes in rapidly advancing biologic and cell therapy programs, offering analytical testing, process development, and manufacturing services to pharmaceutical and biotech companies at its facilities in San Antonio, TX.
Scorpius Holdings, Inc. (NYSE American: SCPX), a contract development and manufacturing organization (CDMO), has announced the pricing of a public offering of 12,500,000 shares of common stock or pre-funded warrants at $1.00 per share. The offering is expected to raise approximately $12,500,000 in gross proceeds. The company has also granted underwriters a 45-day option to purchase up to an additional 1,875,000 shares or warrants to cover over-allotments. Scorpius plans to use the net proceeds for working capital and general corporate purposes. The offering is set to close on August 19, 2024, with trading of SCPX expected to resume on the same day. ThinkEquity is acting as the sole book-running manager for this offering.
Scorpius Holdings (NYSE American: SCPX) has announced a delay in its previously announced public offering. The company has received approval from NYSE for a financial viability exception to shareholder approval rules, allowing it to proceed with an underwritten public offering. Scorpius intends to offer 12,500,000 shares of common stock (or pre-funded warrants) at $1.00 per share. The previous underwriting agreement was terminated, and a new one will be entered if the offering is consummated. The closing is intended to occur ten days after notifying shareholders. Proceeds will fund working capital and general corporate purposes. ThinkEquity is the sole book-running manager. A registration statement has been filed with the SEC and became effective on August 6, 2024.
Scorpius Holdings (NYSE American: SCPX), a contract development and manufacturing organization (CDMO), has announced the removal of its NYSE American trading suspension. The company's common stock is expected to resume normal trading on August 2, 2024, under the symbol 'SCPX'.
The NYSE Regulation staff has withdrawn its delisting determination after confirming that Scorpius' stock is now trading above the low selling price threshold defined in Section 1003(f)(v) of the NYSE American Company Guide. This development allows Scorpius to maintain its listing on the NYSE American exchange.
Scorpius Holdings specializes in rapidly advancing biologic and cell therapy programs, offering analytical testing, process development, and manufacturing services to pharmaceutical and biotech companies at its facilities in San Antonio, Texas.
